论文部分内容阅读
Objective: The aim of the study was to determine the safety and efficacy of 125I-seed implantation in combination with nimotuzumab immunotherapy in patients with advanced oral carcinoma.Methods: 11 patients with advanced oral carcinoma (7 cases of squamous cell carcinoma and 4 cases of poorly differentiated adenocarcinoma) were enrolled in this study.The patients did not receive surgery.All of them underwent 125I-seed implantation with the matched peripheral doses (MPD) ranging from 90-120Gy.The apparent activity per seed ranged from 0.6mCi (2.22MBq) to 0.7mCi (2.59MBq).Later, all patients were given nimotuzumab (200mg,intravenous drip, weekly, for 6 weeks).The evaluation of therapeutic effficacy was mainly based on the Response Evaluation Criteria in Solid Tumors (RECIST).Acute radiation-induced injuries were evaluated using the grading criteria developed by Radiation Treatment Oncology Group (RTOG) and European Organization for Research on Treatment of Cancer (EORTC).The adverse events of Nimotuzumab were evaluated according to the guidelines of National Cancer Institute Common Toxicity Criteria version 3.0 (CTC3.0).The study was approved by the hospitals ethics committee.